5/5Apimeds Pharmaceuticals US, Inc. (APUS): Late annual report (NT 10-K)

Market data

Price before filing: $17.5 (2026-03-30 close, split/dividend-adjusted)
Market cap at flag: $27.8M (2026-03-31) · Latest: $6.6M (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-31 to 2026-04-30. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

What this means

The company told the SEC it could not file its annual report on time (Form NT 10-K) and then missed the 15-day extension too. Late annual reports often precede restatements, auditor problems or going-concern warnings.

Status: filed late (report filed 2026-05-04)

Why this score: filed late on 2026-05-04; also within 90 days: Going-concern doubt, Late quarterly report (NT 10-Q)